- Home
- HAIA vs ALRN Comparison
HAIA vs ALRN Comparison
Compare HAIA & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAIA
- ALRN
- Stock Information
- Founded
- HAIA 2021
- ALRN 2001
- Country
- HAIA United States
- ALRN United States
- Employees
- HAIA N/A
- ALRN N/A
- Industry
- HAIA Blank Checks
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- HAIA Finance
- ALRN Health Care
- Exchange
- HAIA Nasdaq
- ALRN Nasdaq
- Market Cap
- HAIA 68.8M
- ALRN 76.9M
- IPO Year
- HAIA 2021
- ALRN 2017
- Fundamental
- Price
- HAIA $11.50
- ALRN $3.42
- Analyst Decision
- HAIA
- ALRN Strong Buy
- Analyst Count
- HAIA 0
- ALRN 1
- Target Price
- HAIA N/A
- ALRN $19.00
- AVG Volume (30 Days)
- HAIA 6.5K
- ALRN 93.8K
- Earning Date
- HAIA 01-01-0001
- ALRN 11-26-2024
- Dividend Yield
- HAIA N/A
- ALRN N/A
- EPS Growth
- HAIA N/A
- ALRN N/A
- EPS
- HAIA 0.13
- ALRN N/A
- Revenue
- HAIA N/A
- ALRN N/A
- Revenue This Year
- HAIA N/A
- ALRN N/A
- Revenue Next Year
- HAIA N/A
- ALRN N/A
- P/E Ratio
- HAIA $85.61
- ALRN N/A
- Revenue Growth
- HAIA N/A
- ALRN N/A
- 52 Week Low
- HAIA $10.84
- ALRN $1.57
- 52 Week High
- HAIA $11.53
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- HAIA 64.85
- ALRN 47.41
- Support Level
- HAIA $11.49
- ALRN $3.37
- Resistance Level
- HAIA $11.52
- ALRN $3.92
- Average True Range (ATR)
- HAIA 0.04
- ALRN 0.35
- MACD
- HAIA 0.00
- ALRN -0.06
- Stochastic Oscillator
- HAIA 83.81
- ALRN 21.36
About HAIA Healthcare AI Acquisition Corp.
Healthcare AI Acquisition Corp is a blank check company.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.